Table 1 Immunostain assay results, based on two independent TMAs 1 and 2, for 30 randomly selected breast cancer tumor specimens (5 per decade; all FFPE) for: CK cocktail, ER, PR, HER2, CK 5/6, EGFR, Ki67, and molecular phenotype (Kaiser Permanente, Northern California, USA, 1947–2009)
From: Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947–2009)
Year range | ID | Year of diagnosis | Histologic diagnosis | Histologic grade | CK cocktail | ER | PR | HER2 | CK 5/6 | EGFR | Ki67 | Molecular phenotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | TMA1 | TMA2 | |||||
1947–1959 | 1–1 | 1955 | Invasive carcinoma with ductal and lobular features | 2 | + | + | + | + | − | − | − | − | − | − | − | − | 1.3% | 0.3% | Luminal A | Luminal A |
1–2 | 1957 | IDC | 2 | + | + | + | + | + | + | 3+ | 3+ | − | − | − | − | 9.0% | 4.7% | Luminal B | Luminal B | |
1–3 | 1959 | IDC | 3 | + | + | + | + | + | + | − | − | − | − | − | − | 2.7% | 5.3% | Luminal A | Luminal A | |
1–4 | 1956 | Invasive lobular carcinoma | 2 | + | + | + | + | + | + | − | − | − | − | − | − | 1.3% | 2.0% | Luminal A | Luminal A | |
1–5 | 1956 | IDC | 3 | − | − | − | − | − | − | − | − | − | − | − | − | 12.3% | 12.7% | Unclassifiable | Unclassifiable | |
1960–1969 | 2–6 | 1968 | Solid papillary carcinoma | 2 | + | + | + | + | + | + | − | − | − | − | − | − | 3.0% | 3.3% | Luminal A | Luminal A |
2–7 | 1969 | IDC | 3 | + | + | − | − | − | − | 2+ | 2+ | − | − | + | − | 23.0% | 18.0% | Basal-like | Unclassifiable | |
2–8 | 1969 | IDC | 2 | + | + | + | + | + | + | 3+ | 3+ | − | − | − | − | 9.0% | 5.7% | Luminal B | Luminal B | |
2–9 | 1968 | Invasive mucinous carcinoma | 2 | − | − | + | + | + | + | − | − | − | − | − | − | 2.7% | 4.0% | Luminal A | Luminal A | |
2–10 | 1965 | IDC with medullary features | 3 | + | + | − | − | − | − | − | − | − | + | + | + | 7.0% | 5.0% | Basal-like | Basal-like | |
1970–1979 | 3–11 | 1973 | IDC | 1 | + | + | + | + | + | + | − | − | − | − | − | − | 6.0% | 4.7% | Luminal A | Luminal A |
3–12 | 1974 | IDC | 3 | + | + | + | + | + | + | − | − | − | − | − | − | 6.0% | 7.3% | Luminal A | Luminal A | |
3–13 | 1977 | IDC | 3 | a | + | a | + | a | + | a | − | a | − | a | − | a | 16.3% | a | Luminal B | |
3–14 | 1979 | Solid papillary carcinoma | 2 | + | + | + | + | + | + | − | − | + | + | − | − | 1.7% | 2.5% | Luminal A | Luminal A | |
3–15 | 1974 | IDC | 3 | + | + | − | − | − | − | 3+ | 3+ | + | − | − | − | 8.7% | 8.0% | HER2 | HER2 | |
1980–1989 | 4–16 | 1988 | IDC | 3 | + | + | + | + | + | + | − | − | − | − | − | − | 2.0% | 2.0% | Luminal A | Luminal A |
4–17 | 1980 | IDC | 3 | + | + | − | − | − | − | − | − | − | − | − | − | 9.7% | 7.3% | Unclassifiable | Unclassifiable | |
4–18 | 1985 | IDC | 3 | + | + | + | + | + | − | − | − | − | − | − | − | 10.0% | 3.5% | Luminal A | Luminal A | |
4–19 | 1986 | Tubular carcinoma | 1 | + | + | + | + | − | − | − | b | − | − | − | − | 1.3% | 1.0% | Luminal A | Unknown | |
4–20 | 1985 | IDC | 1 | + | + | + | + | − | + | − | − | − | − | − | − | 1.0% | 0.5% | Luminal A | Luminal A | |
1990–1999 | 5–21 | 1999 | IDC | 3 | + | + | − | − | − | − | 3+ | 3+ | − | − | − | − | 12.7% | 13.3% | HER 2 | HER 2 |
5–22 | 1994 | Mixed IDC and mucinous carcinoma | 3 | + | + | + | + | + | + | − | − | − | − | − | − | 9.3% | 11.0% | Luminal A | Luminal A | |
5–23 | 1996 | Invasive carcinoma with ductal and lobular features | 2 | + | + | + | + | + | + | − | − | − | − | − | − | 1.7% | 3.5% | Luminal A | Luminal A | |
5–24 | 1995 | Invasive carcinoma with ductal and lobular features | 2 | + | + | + | + | + | + | − | − | − | − | − | − | 16.0% | 8.0% | Luminal B | Luminal A | |
5–25 | 1998 | Invasive carcinoma with ductal and lobular features | 2 | + | + | + | + | − | − | − | − | − | − | − | − | 5.7% | 7.7% | Luminal A | Luminal A | |
2000–2009 | 6–26 | 2006 | IDC | 3 | + | + | + | + | + | + | 3+ | 3+ | − | − | − | − | 17.7% | 12.0% | Luminal B | Luminal B |
6–27 | 2002 | IDC | 3 | + | + | − | − | − | − | 3+ | 3+ | − | − | − | − | 13.3% | 14.0% | HER 2 | HER 2 | |
6–28 | 2000 | Invasive carcinoma with ductal and lobular features | 2 | + | + | + | + | + | + | − | b | − | − | − | − | 5.7% | 8.3% | Luminal A | Luminal A or Luminal B | |
6–29 | 2002 | IDC with medullary features | 3 | + | + | − | − | − | − | 2+ | − | + | + | + | + | 6.3% | 7.7% | Basal-like | Basal-like | |
6–30 | 2000 | IDC | 3 | + | + | + | + | + | + | − | − | − | − | − | − | 6.3% | 6.7% | Luminal A | Luminal A | |
Percent concordance | 100% | 100% | 93% | 97% | 93% | 97% | 90% | 90% | ||||||||||||
Kappa (95% confidence interval) | 1.000 (1.000, 1.000) | 1.000 (1.000, 1.000) | 0.926 (0.705, 1.000) | 0.908 (0.731, 1.000) | 0.628 (0.155, 1.000) | 0.782 (0.372, 1.000) | 0.346 c (−0.225, 0.916) | 0.724 (0.591, 0.976) | ||||||||||||
